Cyclo-oxygenase and colon cancer: Clues to the aspirin effect?

Annals of Medicine

Volumn 29, Issue 3, 1997, Pages 247-252

  Gustafson Svärd, Christina ^a,b   Lilja, Ingela ^a   Hallböök, Olof ^a   Sjödahl, Rune ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Baltic Intl School of Public Health   (Sweden)

Author keywords

Colon cancer; Cyclo oxygenase; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE;

CANCER RISK; COLON CANCER; COLON CARCINOGENESIS; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STOMACH ULCER;

EID: 0030761645     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899708999342     Document Type: Review

References (68)

1. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241-6.
2. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5: 138-46.
3. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer 1994; 74: 1847-54.
4. Kauppi M, Pukkala E, Isomäki H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exp Rheumatol 1996; 14: 551-3.
5. Giovannucci E, Egan K, Hunter D, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609-14.
6. Kune G, Kune S, Watson L. Colorectal cancer risk, chronic illness, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-404.
7. Suh O, Mettlin C, Petrelli N. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993; 72: 1171-7.
8. Thun M, Namboodiri M, Calle E, Flanders W, Heath C. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-7.
9. Rigau J, Pique J, Rubio E, Planas R, Tarrech J, Bordas J. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991; 115: 952-4.
10. Spagnesi M, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994; 106: 362-6.
11. Waddell W, Gasner G, Cerise E, Loughry R. Sulindac for polyposis of the colon. Am J Surg 1989; 157: 175-9.
12. Hirota C, Iida M, Aoyagi K, et al. Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis. Cancer 1996; 78: 1660-5.
13. Mereto E, Frencia L, Ghia M. Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine. Cancer Lett 1994; 76: 5-9.
14. Metzger U, Meier J, Uhlschmid G, Weihe H. Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis Colon Rectum 1984; 27: 366-9.
15. Reddy BS, Tokumo K, Kulkarni N, Aligia C, Kelloff G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 1992; 13: 1019-23.
16. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14: 1493-7.
17. Pollard M, Luckert P. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 1981; 214: 558-9.
18. Reddy B, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987; 47: 5340-6.
19. Skinner S, Penney A, Penney G, O'Brian P. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg 1991; 26: 1094-6.
20. Jacoby R, Marshall D, Newton M, et al. Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996; 56: 710-4.
21. Kudo I, Murakami M, Kara S, Inoue K. Mammalian non-pancreatic phospholipases A2. Biochim Biophys Acta 1993; 117: 217-31.
22. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263: F181-91.
23. Yokoyama C, Tanabe T. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun 1989; 165: 888-94.
24. Hia T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992; 89: 7384-8.
25. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049-54.
26. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156-60.
27. Crofford LJ, Wilder RL, Ristimäki AP, et al. Cyclo-oxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbol ester, and corticosteroids. J Clin Invest 1994; 93: 1095-101.
28. Habib A, Créminon C, Frobert Y, Grassi J, Pradelles P, Maclouf J. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. J Biol Chem 1993; 31: 23448-54.
29. Rzymkiewicz D, Leingang K, Baird N, Morrison AR. Regulation of prostaglandin endoperoxide synthase gene expression in rat mesangial cells by interleukin-1β. Am J Physiol 1994; 266: F39-45.
30. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8.
31. Gustafson-Svärd C, Lilja I, Sjödahl R, Tagesson C. Cytosolic phospholipase A2 and cyclooxygenase-2 mediate release and metabolism of arachidonic acid in tumor necrosis factor-α-primed cultured intestinal epithelial cells (INT 407). Scand J Gastroenterol 1995; 30: 1000-7.
32. DuBois RN, Tsujii M, Bishop P, Awad JA, Makita K, Lanahan A. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am J Physiol 1994; 266: G822-7.
33. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-32.
34. Vane J, Botting R. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol 1996; 25: 9-21.
35. Kargman S, Charleson S, Cartwright M, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996; 111: 445-54.
36. Earnest DL, Hixson LJ, Alberts DS. Piroxicam and other cyclooxygenase inhibitors. Potential for cancer chemoprevention. J Cell Biochem 1992; Supplement 161: 156-66.
37. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-89.
38. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Cell Biol 1993; 268: 6610-4.
39. Klein T, Nüsing R, Pfeilschifter J, Ullrich V. Selective inhibition of cyclooxygenase 2. Biochem J 1994; 48: 1605-10.
40. Bennett A, Civier A, Hensby CN, Melhuish PB, Stamford IF. Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues. Gut 1987; 28: 315-8.
41. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518-23.
42. Hendrickse CW, Kelly RW, Radley S, Donovan IA, Keighley MRB, Neoptolemos JP. Lipid peroxidation and prostaglandins in colorectal cancer. Br J Surg 1994; 81: 1219-23.
43. Yamaguchi A, Ishida T, Nishimura G, Katoh M, Miyazaki I. Investigation of colonic prostaglandins in carcinogenesis in the rat colon. Dis Colon Rectum 1991; 34: 572-6.
44. Pelus L, Strausser H. Prostaglandins and the immune response. Life Sci 1977; 20: 903-14.
45. Young M, Dizer M. Enhancement of immune function and tumor growth inhibition by antibodies against prostaglandin E2. Immunol Commun 1983; 12: 11-23.
46. Arvind P, Papavassiliou E, Tsioulias G, et al. Prostaglandin E2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines. Biochemistry 1995; 34: 5604-9.
47. Qiao L, Kozoni V, Tsioulias GJ, et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1995; 1258: 215-23.
48. Uribe A, Alam M, Midtvedt T. E2 prostaglandins modulate cell proliferation in the small intestinal epithelium of the rat. Digestion 1992; 52: 157-64.
49. Pugh S, Thomas GAO. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994; 35: 675-8.
50. Rao CV, Simi B, Reddy BS. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 1993; 14: 2219-25.
51. Rao CV, Desai D, Simi B, Kulkarni N, Amin S, Reddy BS. Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon. Cancer Res 1993; 53: 4182-8.
52. Boolbol S, Dannenberg A, Chadburn A, et al. Cyclo-oxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56: 2556-60.
53. Rao CV, Simi B, Wynn T-T, Garr K, Reddy BS. Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats. Cancer Res 1996; 56: 532-7.
54. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785-9.
55. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55: 2556-9.
56. Kutchera W, Jones D, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996; 93: 4816-20.
57. Gustafson-Svärd C, Lilja I, Hallböök O, Sjödahl R. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut 1996; 38: 79-84.
58. DuBois RN, Radhika A, Reddy BS, Entigh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996; 110: 1259-62.
59. Williams C, Luongo C, Radhika A, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996; 111: 1134-40.
60. Reddy B, Rao C, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566-9.
61. Takahashi M, Fukutake M, Yokota S, Ishida K, Wakabayashi K, Sugimura T. Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. J Cancer Res Clin Oncol 1996; 122: 219-22.
62. 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-9.
63. Tsuji M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
64. DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 1996; 56: 733-7.
65. Plummer SM, Hall M, Faux SP. Oxidation and genotoxicity of fecapentaene-12 are potentiated by prostaglandin H synthase. Carcinogenesis 1995; 16: 1023-8.
66. Clària J, Lee M, Serhan C. Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol Med 1996; 2: 583-96.
67. Clària J, Serhan C. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 1995; 92: 9475-9.
68. Bozza P, Payne J, Morham S, Langenbach R, Smithies O, Weller P. Leukocyte lipid body formation and eicosanoid generation: cyclooxygenase-independent inhibition by aspirin. Proc Natl Acad Sci USA 1996; 93: 11091-6.